10-Q: HeartBeam Faces Going Concern Amid Rising Losses

HeartBeam, Inc. reported increased net losses and cash burn, raising substantial doubt about its ability to continue as a going concern, despite recent FDA clearances and successful capital raises.

Summary

• HeartBeam, Inc. reported a net loss of $4.974 million for the three months ended June 30, 2025, compared to $4.956 million for the same period in 2024.
• The net loss for the six months ended June 30, 2025, was $10.458 million, an increase from $9.562 million for the six months ended June 30, 2024.
• Cash and cash equivalents, combined with short-term investments, totaled approximately $5.1 million as of June 30, 2025.
• The company believes its existing liquidity is insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• Research and development (R&D) expenses increased by 17% to $3.326 million for the three months ended June 30, 2025, and by 29% to $6.818 million for the six months ended June 30, 2025.
• General and administrative (G&A) expenses decreased by 25% to $1.711 million for the three months ended June 30, 2025, and by 19% to $3.720 million for the six months ended June 30, 2025.
• Net cash used in operating activities was $7.922 million for the six months ended June 30, 2025, up from $7.013 million in the prior year period.
• The company raised approximately $10.3 million in net proceeds from a public offering in February 2025 and an additional $0.450 million from its At-the-Market (ATM) program during the six months ended June 30, 2025.
• HeartBeam has approximately $15.6 million available for issuance under its ATM sales agreement as of the financial statement issuance date.
• The VALID-ECG pivotal study successfully met its clinical endpoints in April 2025, demonstrating a 93.4% overall diagnostic agreement for HeartBeam's synthesized 12-lead ECG compared to standard 12-lead ECGs for arrhythmia assessment.
• The company initiated an Early Access Program for the HeartBeam System to gather feedback on user experience and workflow, with no anticipated revenue generation from this program.
• HeartBeam announced a strategic collaboration with AccurKardia in April 2025 to integrate their FDA-cleared, automated ECG interpretation platform, aiming to expedite product development and reduce costs/timelines.

Sentiment

Score: 4

Explanation: The sentiment is mixed to negative. While the company achieved significant clinical and regulatory milestones (FDA clearance, successful pivotal study, new patents) and successfully raised capital, the substantial increase in net loss and cash burn, coupled with the explicit 'going concern' warning and the stated insufficiency of current liquidity for the next 12 months, overshadows the operational progress. The reliance on future capital raises without guaranteed terms presents a significant financial risk.

Positives

• FDA clearance for the initial patient-held ECG device was granted on December 13, 2024.
• The company filed a 510(k) notification for software algorithms to synthesize a 12-lead ECG in January 2025, progressing towards a comprehensive ambulatory device.
• The VALID-ECG pivotal study successfully met clinical endpoints in April 2025, showing a high 93.4% overall diagnostic agreement for arrhythmia assessment.
• A strategic collaboration with AccurKardia is expected to enhance the commercial offering with automated ECG interpretation, potentially reducing product development costs and timelines.
• The company successfully raised approximately $10.3 million in net proceeds from a public offering in February 2025, significantly bolstering its cash position.
• HeartBeam continues to expand its intellectual property portfolio, having been granted two new U.S. patents and receiving a Notice of Allowance for an additional U.S. patent application in 2025, bringing the total to 21 issued patents worldwide.
• General and administrative expenses decreased by 25% for the three months and 19% for the six months ended June 30, 2025, primarily due to lower stock-based compensation and consultant costs.

Negatives

• The company has incurred losses each year since inception and experienced negative cash flows from operations in each year since inception.
• Existing liquidity of approximately $5.1 million (cash and short-term investments) is deemed insufficient to fund operations for the next twelve months, raising substantial doubt about the company's ability to continue as a going concern.
• Net loss increased to $10.458 million for the six months ended June 30, 2025, compared to $9.562 million in the prior year period.
• Net cash used in operating activities increased to $7.922 million for the six months ended June 30, 2025, from $7.013 million in the prior year period, indicating a higher cash burn rate.
• The company expects no material commercial revenue in 2025.

Risks

• The company's ability to continue as a going concern is uncertain and depends on its ability to raise additional capital through equity and/or debt financings or strategic relationships.
• There is no assurance that necessary financing or strategic relationships will be available on acceptable terms, or at all.
• The company faces difficulties inherent in the development of a commercial market for its products.
• Significant competition exists from larger companies, other technology companies, and alternative technologies.
• The company's operations are dependent on key individuals and product candidates.
• Actual results may differ materially and adversely from forward-looking statements due to various risks and uncertainties.

Future Outlook

The company expects no material commercial revenue in 2025. Its continued operations and commercialization plan depend on raising additional capital through equity and/or debt financings or strategic relationships. The company is continuing commercial readiness activities in advance of an anticipated commercial launch, which will occur once FDA clearance for its 12-lead synthesis software is received. Management anticipates FDA clearance for the 12-lead synthesis product by December 31, 2025. The company intends to balance headcount management with cash resources while hiring or engaging additional professionals in alignment with its growth strategy, focusing on executing growth opportunities and investing in new technologies through partnerships and acquisitions.

Management Comments

• Management believes the continued achievement of these milestones will provide the company the ability to raise additional capital.

Industry Context

HeartBeam operates in the rapidly growing field of ambulatory cardiac health monitoring, aiming to transform cardiac care through higher resolution ECG solutions. Its focus on developing a portable, patient-carried device that can synthesize a 12-lead ECG positions it to address a significant market need for remote cardiac diagnostics, potentially disrupting traditional hospital-based ECG systems. The strategic collaboration with AccurKardia for automated ECG interpretation aligns with the broader industry trend towards AI-driven diagnostics and enhanced efficiency in healthcare.

Comparison to Industry Standards

• The company's proprietary ECG technology platform is capable of developing three-dimensional (3D) representations of cardiac electrical activity, which early studies demonstrated to deliver diagnostic capability equal or superior to traditional hospital-based ECG systems.
• The HeartBeam System's approach has demonstrated diagnostic insights similar to a standard 12-lead ECG for arrhythmia assessment.
• The VALID-ECG pivotal study showed a 93.4% overall diagnostic agreement between HeartBeam's synthesized 12-lead ECG and a simultaneously collected standard 12-lead ECG, indicating consistency with standard 12-lead ECGs for arrhythmia diagnosis.

Corporate Governance

Related Party Transactions

• During April 2024, the company entered into a consulting agreement with an independent Board of Director member to provide business development consulting services, paying $5,000 per month and granting 70,000 options vesting over 36 months. For the six months ended June 30, 2025, $51,000 was recognized related to these services, including $21,000 in stock-based compensation expense.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and potential future equity raises (public offering, ATM program) to fund operations. The 'going concern' warning indicates high financial risk.
• **Employees**: Stock-based compensation is a significant component of compensation, with unvested options and RSUs totaling approximately $8.1 million and $0.1 million, respectively. The company intends to manage headcount in line with cash resources.
• **Customers/Healthcare Providers**: Will benefit from the development and anticipated commercialization of higher-resolution ambulatory ECG solutions, including the 12-lead synthesis software and automated interpretation, offering improved diagnostic capabilities outside traditional settings.
• **Creditors**: The 'going concern' warning and reliance on future capital raises may increase perceived credit risk.

Next Steps

• Receive FDA clearance for the software algorithms that synthesize a 12-lead ECG from the HeartBeam System.
• Commercialize the HeartBeam System and 12-lead synthesis software upon FDA clearance.
• Continue the Early Access Program to gather feedback on user experience and workflow.
• Integrate AccurKardia's automated ECG interpretation platform into the product offering.
• Continue AI program development, leveraging acquired 12-lead ECG data.
• Raise additional capital through equity and/or debt financings or strategic relationships to fund operations.
• Manage headcount in line with cash resources and hire/engage additional professionals as part of growth strategy.

Key Dates

Recommendation

Despite significant progress in product development, regulatory clearances, and a recent capital raise, the explicit 'going concern' warning is a critical red flag. The company's current cash and short-term investments are insufficient to fund operations for the next 12 months, and it expects no material commercial revenue in 2025. This indicates a high probability of further dilutive capital raises or potential operational distress if funding is not secured on acceptable terms. The increasing net loss and cash burn further exacerbate the financial instability. While the technology shows promise, the immediate financial outlook presents substantial risk to capital.

Keywords

Cardiac technology, ECG solutions, Ambulatory monitoring, FDA clearance, Medical devices, HeartBeam System, 12-lead ECG, Arrhythmia assessment, Telehealth, Digital health, MedTech, Going concern, Capital raise, Clinical trials, Intellectual property